79 research outputs found
κ³νλ±μ μ±λΆμ°κ΅¬
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : μ½νλν μ½νκ³Ό, 2016. 2. μ μ’
ν.ν¨μ sortase Aμ λν΄ μ ν΄ μ리νμ±μ κ°μ§λ μ²μ° λ¬Όμ§μ μ°Ύκ³ μ λ€μν μμ½ μΆμΆλ¬Όμ νκ°νμλ€. μ리νμ± κ²μ κ²°κ³Όμ λ°λΌ κ³νλ±μ μ°κ΅¬λμμΌλ‘ μ ννμλλ° μ΄λ νμ‘μν κ°μ κ³Ό μ리ν΅, λΉν, λ§λΉ, κ΄μ ν΅ λ° μΈκ· κ°μΌμ μ¬μ©λλ μ ν΅ μμ½μ΄λ€. Sortase Aμ λ€νμ¬ λμ μ ν΄νμ±μ 보μ΄λ κ³νλ± μΆμΆλ¬Όμ λΆνμ λνμ¬ λ€μν ν¬λ‘λ§ν κ·ΈλνΌ λΆλ¦¬ κΈ°λ²μΌλ‘ μ΄ 20κ°μ λ¬Όμ§μ λΆλ¦¬νμλ€. 볡ν©μ λΆκ΄νμ λΆμμ κ²°κ³Όλ₯Ό ν λλ‘ λΆλ¦¬λ λ¬Όμ§λ€μ΄ 18μ’
μ flavonoids, 1μ’
μ phenolic, 1μ’
μ flavonoid dimer μμ λμ νμλ€. μ΄λ€ μ€ 3μ’
μ flavonoid κ³μ΄ λ¬Όμ§μ΄ κ³νλ±μμλ μ²μ λ°κ²¬λ λ¬Όμ§μμ νμΈνμλ€.For the investigation of bioactive natural products with sortase A (SrtA) inhibitory effect, various extracts of Korean herbal medicines were evaluated. Based upon the results of bioactivity screening, the dried vine stem of Spatholobus suberectus Dunn. which is an oriental folk medicine used mainly for the improvement of blood circulation and treatment for dysmenorrhea, anemia, paralysis, arthralgia and bacterial infections was selected for chemical investigation. The large-scale extraction followed by the bioactivity-guided partition and chromatographic separation yielded twenty compounds. Based upon the results of combined spectroscopic analyses, these compounds were structurally identified as eighteen flavonoids, one flavonoid dimer and a phenolic compound. Among these three flavonoids were found from this plant for the first time.Introduction 1
Experimental Section 3
1. General Experimental Procedures 3
2. Plant Material 3
3. Extraction and Isolation 3
Results 7
1. Compound 1 7
2. Compound 2 7
3. Compound 3 8
4. Compound 4 9
5. Compound 5 9
6. Compound 6 10
7. Compound 7 10
8. Compound 8 11
9. Compound 9 12
10. Compound 10 12
11. Compound 11 13
12. Compound 12 13
13. Compound 13 13
14. Compound 14 14
15. Compound 15 14
16. Compound 16 14
17. Compound 17 15
18. Compound 18 15
19. Compound 19 16
20. Compound 20 16
Discussion 38
References 39
Abstract in Korean 52Maste
Involvement of TGF-{beta} receptor- and integrin-mediated signaling pathways in the pathogenesis of granular corneal dystrophy II
Purpose. The purpose of this study was to elucidate the pathophysiological process in primary cultured corneal fibroblasts (PCFs) from normal subjects and granular corneal dystrophy (GCD) II patients, by using cDNA microarrays. Methods. PCFs were isolated from the corneas of normal subjects and GCD II patients who were heterozygous and homozygous for the TGFBI R124H mutation. RNA was isolated from each sample, and gene expression profiles were analyzed with a cDNA microarray consisting of approximately 29,000 genes. Cell adhesion assays were performed to confirm the functionality of the detected gene expression profiles. Results. Twofold differences were detected in the expression of 555 genes between wild-type and homozygous GCD II PCFs. Of these, 319 genes were upregulated, and 236 genes were downregulated in the homozygous GCD II PCFs. The most abundant and consistent changes were observed in gene families encoding signal transduction pathways involving the TGF-beta receptor- and integrin-mediated signaling, cell differentiation and proliferation, immune responses, cell adhesion, extracellular matrix (ECM) proteolytic enzymes, cell cycle, cytoskeletal organization, mitochondrial energy metabolism, collagen catabolism, response to wounding, response to oxidative stress, and the ubiquitin-mediated proteasomal degradation pathway. Cell adhesion assays demonstrated that heterozygous and homozygous GCD II PCFs strongly attached to collagen-I, collagen-IV, fibronectin, and laminin, compared with wild-type cells. Conclusions. Alterations in the TGF-beta receptor- and integrin-mediated signaling pathway may play a key role in GCD II pathophysiology. If the novel factors identified in this study are involved in GCD II pathogenesis, they could assist in designing further studies to elucidate specific mechanisms of this diseaseope
Decreased catalase expression and increased susceptibility to oxidative stress in primary cultured corneal fibroblasts from patients with granular corneal dystrophy type II.
Granular corneal dystrophy type II (GCD II) is an autosomal dominant disorder characterized by age-dependent progressive accumulation of transforming growth factor-beta-induced protein (TGFBIp) deposits in the corneal stroma. Several studies have suggested that corneal fibroblasts may decline with age in response to oxidative stress. To investigate whether oxidative stress is involved in the pathogenesis of GCD II, we assayed antioxidant enzymes, oxidative damage, and susceptibility to reactive oxygen species-induced cell death in primary cultured corneal fibroblasts (PCFs) from GCD II patients and healthy subjects. We found elevated protein levels of Mn-superoxide dismutase, Cu/Zn-superoxide dismutase, glutathione peroxidase, and glutathione reductase, as well as increased CAT mRNA and decreased catalase protein in GCD II PCFs. Furthermore, catalase is down-regulated in normal PCFs transfected with transforming growth factor-beta-induced gene-h3. We also observed an increase in not only intracellular reactive oxygen species and H(2)O(2) levels, but also malondialdehyde, 4-hydroxynonenal, and protein carbonyls levels in GCD II PCFs. Greater immunoreactivity for malondialdehyde was observed in the corneal tissue of GCD II patients. In addition, we observed a decrease in Bcl-2 and Bcl-xL levels and an increase in Bax and Bok levels in GCD II PCFs. Finally, GCD II PCFs are more susceptible to H(2)O(2)-induced cell death. Together, these results suggest that oxidative damage induced by decreased catalase is involved in GCD II pathogenesis, and antioxidant agents represent a possible treatment strategyope
The performance of cobalt containing NOx storage reduction catalysts In situ IR study
Maste
νκ΄ μνν μ ꡬμΈν¬μ λΆλ¦¬μ μνν λλ ν μνν λΆν μ λ
νμλ
Όλ¬Έ (λ°μ¬)-- μμΈλνκ΅ λνμ : μνκ³Ό, 2011.8. ꡬ본κΆ.Docto
The Effects of Job Stress Factors of APO(Anti-Abuse Police Officer) on Job Transfer Intention - Focusing on Mediating role of Exhaustion and Moderating effects of Incentives and Social Support -
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : νμ λνμ νμ νκ³Ό(νμ νμ 곡), 2018. 8. λ°μ ν.λ³Έ μ°κ΅¬λ νλμλ°©κ²½μ°°κ΄(APO, Anti-Abuse Police Officer)μ μ¦μ 보μ§μ΄λμ΄ μ§λ¬΄μ€νΈλ μ€μ μμ§μΌλ‘ μΈν΄ λνλλ€κ³ λ³΄κ³ μ§λ¬΄μ€νΈλ μ€κ° 보μ§μ΄λμλμ λ―ΈμΉλ μν₯μ λΆμνλ κ²μ λͺ©μ μΌλ‘ νμλ€.
κΈ°μ‘΄μ κ°μ νλ ₯μ λν μ°κ΅¬λ€μ΄ λ²μ , μ λμ λ¬Έμ μ κ΄λ ¨νμ¬ λ§μ λ
Όμλ₯Ό μ§νν΄ μμ§λ§ κ°μ νλ ₯μ μ¬μ ν κ·Όμ λμ§ μκ³ μκ³ , κ°μ νλ ₯μ λ€λ£¨λ νμ₯κ²½μ°°κ΄μ λμμ λν μ°κ΅¬λ€λ μμμ§λ§ λ²κ³Ό μ λλ₯Ό μ€μ λ‘ νμ₯μμ μ μ©νλ κ²½μ°°κ΄μ μ
μ₯μμ λ¬Έμ μ μ μ°κ΅¬ν μ¬λ‘λ κ±°μ μ 무ν μ€μ μ΄μλ€. μ΄μ λ³Έ μ°κ΅¬λ κ°μ νλ ₯ νμ₯μμ κ°ν΄μ, νΌν΄μμ μ§μ μ μΌλ‘ μν΅νκ³ κ°μ₯ μ΄κΈ°μ κ°μ
νκ³ μ§μμ μΌλ‘ κ΄λ¦¬νκ² λλ APOλ€μ κ΄μ μμ κ·Έλ€μ΄ κ°μ νλ ₯μ΄λΌλ μκΈ°κ°μ
μ μμ΄ λλΌλ μ΄λ €μμ΄ λ¬΄μμΈμ§ λΆμνκ³ μ νμλ€. λ³Έ μ°κ΅¬λ νλμλ°©κ²½μ°°κ΄(APO)μ λν 첫 μ°κ΅¬μ΄λ©° μ κ΅μ APO 491λͺ
μ λν μ μμ‘°μ¬λ₯Ό ν΅ν΄ μ°κ΅¬κ²°κ³Όλ₯Ό λμΆνμλ€λ μ μμ ν° μμκ° μλ€. APOμ μ§λ¬΄μ€νΈλ μ€ μμΈμ μ‘°μ§κ΄λ ¨, μν κ΄λ ¨, κ΄κ³κ΄λ ¨μΌλ‘ μΈλΆννκ³ μ΄κ²λ€μ΄ 보μ§μ΄λμλμ λ―ΈμΉλ μν₯κ΄κ³μ μ΄λ¬ν κ΄κ³μμ μμ§μ 맀κ°μν , μΈμΌν°λΈ λ° μ¬νμ μ§μμ μ‘°μ ν¨κ³Όλ₯Ό κ²μ¦νκ³ μ νμλ€.
μ΄λ₯Ό μν΄ κ²½μ°°μ² μ°ν μ κ΅μ APO 491λͺ
(κ²Έμ
ν¬ν¨)μ λͺ¨μ§λ¨μΌλ‘ μ μνμ¬ μ μμ‘°μ¬λ₯Ό μ€μνμκ³ , μ‘°μ¬μλ¨μΌλ‘λ μκΈ°κΈ°μ
μ μ¨λΌμΈμ€λ¬Έμ μ¬μ©νμλ€. κ·Έλ¦¬κ³ μΈκ΅¬ν΅κ³νμ λΆμμ μν΄ λΉλλΆμκ³Ό κΈ°μ ν΅κ³λΆμμ μ¬μ©νκ³ , μΈ‘μ λ μ°κ΅¬ κ°λ
λ€μ λν νλΉμ±κ³Ό μ λ’°μ±μ ν보νκΈ° μνμ¬ μμΈλΆμκ³Ό μ λ’°λλΆμμ μ¬μ©νμμΌλ©°, μ€μ λ κ°μ€λ€μ κ²μ¦νκΈ° μν΄ λ€μ€νκ·λΆμκ³Ό μκ³μ νκ·λΆμμ μ€μνμλ€.
κ·Έ κ²°κ³Ό APOμ μ§λ¬΄μ€νΈλ μ€λ 보μ§μ΄λμλμ μ (+)μ μ μν μν₯μ λ―ΈμΉλ€λ κ²μ΄ νμΈλμμΌλ©° λ€λ§, μ§λ¬΄μ€νΈλ μ€μ μΈ κ°μ§ μμΈ μ€ μν μ€νΈλ μ€λ§ μ μλ―Έν μν₯μ λ―ΈμΉμ§ μλ κ²μΌλ‘ λνλ¬λ€.
λν, APOμ μ§λ¬΄μ€νΈλ μ€ μΈ κ°μ§ νμμμΈ(μ‘°μ§, μν , κ΄κ³)μ΄ μμ§μ μΈ κ°μ§ νμ μμΈ(μ μμ κ³ κ°, λΉμΈκ²©ν, μ±μ·¨κ° μ ν)μ μ (+)μ μ μν μν₯μ λ―ΈμΉλ κ²μ΄ νμΈλμλλ° μ΄ λ μ§λ¬΄μ€νΈλ μ€μ μΈ κ°μ§ μμΈμ΄ λͺ¨λ λΉμΈκ²©νμ μ μν μν₯μ λ―Έμ³€μΌλ, μΈ κ°μ§ μμΈ μ€ μν μ€νΈλ μ€λ λΉμΈκ²©νμ μ±μ·¨κ° μ νμλ§, μ‘°μ§ μ€νΈλ μ€λ μ μμ κ³ κ°κ³Ό λΉμΈκ²©νμλ§ μ μν μν₯μ λ―Έμ³€λ€.
μμ§ μμ 보μ§μ΄λμλμ μ (+)μ μ μν μν₯μ λ―ΈμΉλ€λ κ²μ΄ νμΈλμμΌλ©° λ€λ§ μμ§μ μΈ κ°μ§ νμμμΈ μ€ μ μμ κ³ κ°κ³Ό μ±μ·¨κ° μ νλ 보μ§μ΄λμλμ μ μν μν₯μ λ―Έμ³€μΌλ, λΉμΈκ²©νλ 보μ§μ΄λμλμ μ μν μν₯μ λ―ΈμΉμ§ μμλ€.
μ‘°μ ν¨κ³Όμ λν λΆμ κ²°κ³Ό, μΈμΌν°λΈμ μ¬νμ μ§μ λͺ¨λ μ§λ¬΄μ€νΈλ μ€μ μμ§, 보μ§μ΄λμλμ λΆ(-)μ μκ΄κ΄κ³λ₯Ό κ°μ§λ κ²μΌλ‘ λνλ¬μ§λ§ μ μλ―Έν μ‘°μ ν¨κ³Όλ μλ κ²μΌλ‘ λνλ¬λ€. μ΄λ μ§λ¬΄μ€νΈλ μ€μ 보μ§μ΄λμλμ κ΄κ³ λ° μ§λ¬΄μ€νΈλ μ€μ μμ§μ κ΄κ³ λͺ¨λμμ λμΌν κ²°κ³Όλ₯Ό 보μλλ° μ΄λ νμ¬ APOλ€μκ² μ 곡λλ μΈμΌν°λΈ μμ²΄κ° κ±°μ μκ³ APOμ μ
무 μ±κ²©μ μμ¬, λλ£μμ κ΄κ³λ κ·Έλ€λ‘λΆν° μ£Όμ΄μ§λ κΈμ μ μΈ μ쑰보λ€λ μμλΆμμ μ
무μ μμ¬κ²°μ , κ°μ νλ ₯μ¬κ±΄ λΉμ¬μ λλ μ κ΄κΈ°κ΄κ³Όμ κ΄κ³ λ±μμ κ²°μ λλ λΆλΆμ΄ λ§κΈ° λλ¬ΈμΈ κ²μΌλ‘ 보μΈλ€.
μ΄λ¬ν κ³Όμ μ ν΅ν΄ APOμ μ§λ¬΄μ€νΈλ μ€ μμΈμ΄ μ μ΄λμ λ°μνλμ§ μ μ μμμΌλ©°, APOμ μΈλ ₯μ μ¦μνκ±°λ νμ¬ APOμκ² λ§‘κ²¨μ§ μ
무μ λν μμ μ°¨μμμμ μ κ²μ΄ νμν¨μ νμΈν μ μμλ€. νμ¬ λ§‘κ²¨μ§ μ
무λ²μκ° κΌ νμνκ³ νλΉν κ²λ€μ΄λΌλ©΄ κ·Έλ¬ν κ²λ€μ ν¨μ¨μ μΌλ‘ μνν΄ λΌ μ μλ μ μ μΈμμ μ°μΆνμ¬ μΈλ ₯μ μ¦μνμ¬μΌ ν κ²μ΄μ§λ§ νμ¬ λ§‘κ²¨μ§ μ
무λ₯Ό μ‘°μ νμ¬ κ΄λ ¨κΈ°κ΄μΌλ‘ μ΄κ΄νλ κ²μ΄ λ μ μ νλ€λ©΄ μΈλ ₯μ‘°μ μ΄ μλ μ
무μ κ°μ ν΅ν΄ APOμ μ§λ¬΄μ€νΈλ μ€λ₯Ό κ°μμν€κ³ 보μ§μ΄λλ₯ μ μ€μΌ μ μμ κ²μ΄λ€.
λν APOμκ² μνμλΉ, μΉμ§κ°μ , μ λ¬Έμ§μ μΈμ , κ΅μ‘κΈ°ν λΆμ¬ λ± ν¨κ³Όμ μΈ μΈμΌν°λΈμ μ§κΈμ΄ νμνλ©° μΈμΌν°λΈμ λ³κ°λ‘ μ
무μ νμν λΆλΆμ λν λ¬Όμ§μ μ§μ(νΌν΄μ 보νΈβ€μ§μμ νμν μμ°, μ°¨λ, ν΄λν°, μλ΄κ³΅κ° λ§λ ¨ λ±)μ΄ νμν¨μ μ μ μμλ€.
APOλ€μκ² λνλλ λ€μν μ§λ¬΄μ€νΈλ μ€ μμΈμ APO κ°μΈμκ²λ μ 체μ , μ¬λ¦¬μ μΌλ‘ λΆμ μ μν₯μ λ―ΈμΉμ§λ§ κ²°κ΅μλ APO μ
무μ μ§μ μ νλ₯Ό μ΄λνμ¬ λ³΄νΈβ€μ§μμ λ°μμΌ νλ νΌν΄μμκ²λ μ
μν₯μ λ―ΈμΉκ³ κ²½μ°°μ λν μ λ’°λ₯Ό μ νμν€λ μμΈμ΄ λ κ²μ΄λ€. μ¬κΈ°μ λ
Όμν κ²λ€μ ν λλ‘ μ΄μ 5λ
μ°¨μ μ μ΄λ APOμ
무μ λν΄ μ€κ° μ κ²νμ¬ APOλ€μ΄ νμ€μμ λΆλͺμΉκ³ μλ κ°μ’
λ¬Έμ , κ·Έλ‘ μΈν μ§λ¬΄μ€νΈλ μ€μ 근무 νκ²½μ λν μ¬μ‘°λͺ
κ³Ό ν¨κ» κ·Έκ°μ κ³Όμ μμ μ€λ₯λ₯Ό μ°Ύκ³ λ³΄μνλ€λ©΄ APOμ 보μ§μ΄λλ₯ λ μ€μ΄κ³ κ·Έκ²μ κ²°κ΅ μ λ¬Έμ±μ κ°μ§ APOλ€μ μ¦κ°λ‘ κ΅λ―Όλ€μ΄ μ§ λμ κ²½μ°°μλΉμ€λ₯Ό λ°λλ° μΌμ‘°νκ² λ κ²μ΄λ€.μ 1μ₯ μλ‘ 1
μ 1μ μ°κ΅¬μ νμμ± λ° λͺ©μ 1
1. μ°κ΅¬μ νμμ± 1
2. μ°κ΅¬μ λͺ©μ 3
μ 2μ μ°κ΅¬μ λμ, λ²μ λ° λ°©λ² 5
μ 2μ₯ μ΄λ‘ μ λ
Όμμ μ νμ°κ΅¬ κ²ν 6
μ 1μ μ΄λ‘ μ λ
Όμ 6
1. κ°μ νλ ₯μ κ°λ
κ³Ό μ ν 6
(1) κ°μ νλ ₯μ κ°λ
6
(2) κ°μ νλ ₯μ μ ν 7
2. μ§λ¬΄μ€νΈλ μ€μ κ°λ
λ° κ΅¬μ±μμ 8
3. μ§λ¬΄μμ§μ κ°λ
λ° μ μ 9
4. 보μ§μ΄λμλμ κ°λ
λ° μ ν 10
5. μΈμΌν°λΈμ κ°λ
λ° μ ν 11
6. μ¬νμ μ§μμ κ°λ
λ° μ ν 13
(1) μ¬νμ μ§μμ κ°λ
13
(2) μ¬νμ μ§μμ μ ν 14
1) μμ¬μ μ¬νμ μ§μ 15
2) λλ£μ μ¬νμ μ§μ 16
3) κ°μ‘±μ μ¬νμ μ§μ 16
μ 2μ μ νμ°κ΅¬ κ²ν 17
1. κ°μ νλ ₯μ
무 λ΄λΉ κ²½μ°°κ΄μ λν κΈ°μ‘΄ μ νμ°κ΅¬ κ²ν 17
2. 경찰곡무μμ μ§λ¬΄μ€νΈλ μ€μ κ΄ν μ νμ°κ΅¬ κ²ν 19
3. μ§λ¬΄μμ§μ κ΄ν μ νμ°κ΅¬ κ²ν 21
4. μ΄μ§(보μ§μ΄λ)μλμ κ΄ν μ νμ°κ΅¬ κ²ν 22
5. μ§λ¬΄μ€νΈλ μ€, μμ§, μ΄μ§(보μ§μ΄λ)μλ κ° κ΅¬μ‘°μ κ΄κ³μ λν μ νμ°κ΅¬ κ²ν 23
(1) μ§λ¬΄μ€νΈλ μ€μ μμ§μ κ΄κ³λ₯Ό μ΄ν΄λ³Έ μ°κ΅¬ 23
(2) μ§λ¬΄μ€νΈλ μ€μ μ΄μ§(보μ§μ΄λ)μλμ κ΄κ³λ₯Ό μ΄ν΄λ³Έ μ°κ΅¬ 25
(3) μ§λ¬΄μμ§κ³Ό μ΄μ§(보μ§μ΄λ)μλμ κ΄κ³λ₯Ό μ΄ν΄λ³Έ μ°κ΅¬ 25
(4) μμ§μ 맀κ°ν¨κ³Όμ κ΄ν μ νμ°κ΅¬ κ²ν 27
6. μΈμΌν°λΈμ κ΄ν μ νμ°κ΅¬ κ²ν 28
7. μ¬νμ μ§μμ κ΄ν μ νμ°κ΅¬ κ²ν 29
μ 3μ₯ μ°κ΅¬λͺ¨ν(μ°κ΅¬κ°μ€) λ° μ°κ΅¬λ°©λ² 32
μ 1μ μ°κ΅¬λͺ¨ν λ° κ°μ€ μ€μ 32
1. μ°κ΅¬λͺ¨ν 32
2. κ°μ€ μ€μ 33
μ 2μ μ°κ΅¬λ°©λ² 35
1. μ°κ΅¬λμ λ° λ°©λ² 35
2. μΈ‘μ λꡬ 36
(1) λ
립λ³μ : μ§λ¬΄μ€νΈλ μ€μ μΈ‘μ λꡬ 36
(2) 맀κ°λ³μ : μμ§μ μΈ‘μ λꡬ 37
(3) μ’
μλ³μ : 보μ§μ΄λμλμ μΈ‘μ λꡬ 39
(4) μ‘°μ λ³μ : μΈμΌν°λΈμ μΈ‘μ λꡬ 40
(5) μ‘°μ λ³μ : μ¬νμ μ§μμ μΈ‘μ λꡬ 40
(6) ν΅μ λ³μ : μΈκ΅¬ν΅κ³νμ νΉμ± μΈ‘μ λꡬ 42
3. μλ£μ μμ§ λ° λΆμ 44
μ 4μ₯ λΆμκ²°κ³Ό λ° λ
Όμ 46
μ 1μ μ‘°μ¬λμμμ μΈκ΅¬ν΅κ³νμ νΉμ± 46
1. νλ³Έμ κ°μΈ κ΄λ ¨ μΈκ΅¬ν΅κ³νμ νΉμ± 46
2. νλ³Έμ μ‘°μ§ κ΄λ ¨ μΈκ΅¬ν΅κ³νμ νΉμ± 48
μ 2μ μΈ‘μ λꡬμ νλΉμ± λ° μ λ’°μ± λΆμ 50
1. μ§λ¬΄μ€νΈλ μ€μ νλΉμ± λ° μ λ’°μ± λΆμ 52
2. μμ§μ νλΉμ± λ° μ λ’°μ± λΆμ 54
3. 보μ§μ΄λμλμ νλΉμ± λ° μ λ’°μ± λΆμ 55
4. μΈμΌν°λΈμ νλΉμ± λ° μ λ’°μ± λΆμ 56
5. μ¬νμ μ§μμ νλΉμ± λ° μ λ’°μ± λΆμ 57
μ 3μ λ³μμ κΈ°μ΄ν΅κ³λ 58
μ 4μ λ³μ κ°μ μκ΄κ΄κ³ λΆμ 59
μ 5μ κ°μ€ κ²μ¦ 60
1. κ°μ€ 1.μ λν κ²μ¦ 60
2. κ°μ€ 2.μ λν κ²μ¦ 62
3. κ°μ€ 3.μ λν κ²μ¦ 69
4. κ°μ€ 4.μ λν κ²μ¦ 71
5. κ°μ€ 5.μ λν κ²μ¦ 73
6. κ°μ€ 6.μ λν κ²μ¦ 76
7. κ°μ€ 7.μ λν κ²μ¦ 81
μ 5μ₯ κ²°λ‘ 91
μ 1μ μ°κ΅¬κ²°κ³Όμ μμ½ 91
μ 2μ μ°κ΅¬κ²°κ³Όμ μ μ±
μ ν¨μ 94
μ 3μ μ°κ΅¬μ νκ³ λ° ν₯ν μ°κ΅¬λ°©ν₯ 100
μ°Έκ³ λ¬Έν 102
λΆλ‘(μ€λ¬Έμ§) 109Maste
θ¦ε―δ½η¨μΌλ‘μμ θΊ«ε η’Ίθͺμ κ΄ν η‘η©Ά : νλμ€ μ λμμ λΉκ΅λ₯Ό μ€μ¬μΌλ‘
νμλ
Όλ¬Έ(μμ¬) --μμΈλνκ΅ λνμ :λ²νκ³Ό,2007.Maste
A Study of Design Attributes for Specialization at Medical Health Service Design of Public Hospital - Focusing on Medical Health Service Design for Gyeonggi Provincial Medical Center -
μ‘μ μ± μ ν λμμΈνΈλ νν©λ¬Όμ ν©μ±κ³Ό μ€ν©
Thesis (master`s)--μμΈλνκ΅ λνμ :μ¬λ£κ³΅νλΆ,2002.Maste
μΆν 곡μλ Ήμ§μ‘°μ±μ λν μ‘°μ± μ§μΉ¨μ μμ±
β μ£Όλ‘ μκ°νꡬμ μΈκ³½μ λΆν¬νλ λκ·λͺ¨ λ
Ήμ§κ³΅κ°μ λμμ νμ νμ±νκ³ , μ£Όλ―Όλ€μ μνμ μμ μ±μ μ μ§μμΌ μ£Όλ κ°μ₯ κΈ°λ³Έμ μΈ λ
Ήμ§κΈ°λ°μμ€μ΄λΌ ν μ μμ
β νΉν, μκ°νꡬμ κ³³κ³³μ λΆν¬νλ μκ·λͺ¨ λ
Ήμ§κ³΅κ°μ λκ·λͺ¨ λ
Ήμ§κ³΅κ°μ μμ°μνμ κΈ°λ₯μ λ΄ μ§ μκΉμ§ μ°κ²°μμΌ μνκΆ λ΄μμ μμ°μ ννμ λ릴 μ μλλ‘ ν΄μ£Όλ μ€μν λ
Ήμ§κΈ°λ°μμ€μ΄λΌ ν μ μμ
β μΆ©λ¨μμλ νμ¬ κ°κ°μ λͺ©νλ₯Ό κ°μ§ λ€μν ννμ λ
Ήμ§κ³΅κ°λ€μ΄ μ‘°μ±λκ³ μμΌλ©°, κ·Έ λͺ©νλ λ€μκ³Ό κ°μ
- ν볡ν μΆμ 곡μ μ‘°μ± : μλ¦λ΅κ³ κΉ¨λν νκ²½μμ μ΄κ³ μΆμ μ£Όλ―Όμꡬμ λ₯λμ λμ², 200λ§ λλ―Όμ΄ κ°κΎΈκ³ μ΄μ©νλ μΎμ ν λ
Ήμ§ λ° ν΄κ²κ³΅μ μ‘°μ±
- λ΄μ₯νλ¬ΌκΈ° μ¬μ
: νμ λ λμ¬κ³΅κ°μμ λ΄μ₯μ νλ¬Όμ΄ λ
Ήμ§κ³΅κ° ν보, λμ¬μ λΆμ‘±ν λ
Ήμ§νμΆ© λ° μ£Όλ―Ό, νμ λ± νΈμ΅μμ€ μ 곡
- λͺ
νκ°λ‘μ² μ‘°μ± : μ§μνΉμμ λ§λ κ°λ‘μλ₯Ό μμ¬, μ€μ₯κΈ°μ μΌλ‘ κ΄κ΄μμννμ¬ μ κ΅ μ μΌμ λͺ
ν κ°λ‘νκ²½μ μ‘°μ±
- νκ΅μ² μ‘°μ± : νκ΅μ² μ‘°μ±μ ν΅ν μΉμμ°μ μΈ νμ΅κ³΅κ° μ 곡 λ° μνκΆμ λΆμ‘±ν λ
Ήμ§κ³΅κ° νμΆ©
- μ°λ¦Όμ μ μμ보νΈλ¦Ό, 보νΈμ κ΄λ¦¬ : μ°λ¦Όμνκ³ λ³΄μ μΌλ‘ μλ¬Όλ€μμ± μ μ§ λ° μ§μκ°λ₯ν μ°λ¦Όκ΄λ¦¬
- λμμ² μ‘°μ±, κ΄λ¦¬ : λμμ²μ μ‘°μ± λ° κ΄λ¦¬λ‘ κ΅λ―Όλ€μκ² μλ¦λ΅κ³ μΎμ ν λμ λ
Ήμ μννκ²½μ μ 곡νμ¬ βμ²μμ λμ, λμμμ μ²β μ€ν
β κ·Έλ¬λ κ° κ³΅κ°μ λν μ ν©ν μ‘°μ±μ§μΉ¨ μμ΄ κ°λ³μ μΈ κΈ°λ₯ λ° κ°μΉλ₯Ό κ·Ήλνμν€μ§ λͺ»ν μ± μ μ¬ν ννλ‘ μ‘°μ±λκ³ μλ μ€μ μ
β λ°λΌμ μκ°νꡬμ κ³³κ³³μ λΆν¬νλ λ
Ήμ§κ³΅κ°μ μμ°μνμ κΈ°λ₯ λ° μΈκ°ν΄μμ κΈ°λ₯μ ν₯μμν¬ μ μλλ‘ κ° λ
Ήμ§μμ€μ λͺ©νμ μ ν©ν μ‘°μ±μ§μΉ¨μ λ§λ ¨ν νμκ° μμ
- μ΄ν μλ΅β
. μ°κ΅¬μ κ°μ / 3
β
‘. 곡μλ
Ήμ§μ‘°μ±μ νμμ± λ° λͺ©ν / 4
β
’. λͺ©νλ³ κ³΅μλ
Ήμ§ μ‘°μ±μ§μΉ¨ / 6
β
£. μμΉλ³ 곡μλ
Ήμ§λ‘μμ μλ―Έ μ κ³ λ° νμ© λ°©ν₯ / 1
- β¦